BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

por Falchook, G.S., Trent, J.C., Heinrich, M.C, Beadling, C., Patterson, J., Bastida, C.C., Blackman, S.C., Kurzrock, R.
Publicado 2013